{"entity":{"id":"nct04492488","kind":"trial","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","aka":[],"tldr":"A phase 1/2 trial of MRG002 in gastric & gastro-oesophageal junction cancer, run by Shanghai Miracogen Inc., active and no longer recruiting.","summary":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer is a phase 1/2 interventional study registered as NCT04492488 by Shanghai Miracogen Inc., with 129 participants enrolled, started 2021-05-24 and due to reach its primary completion in 2022-10-18. Interventions recorded: MRG002.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04492488","url":"https://clinicaltrials.gov/study/NCT04492488"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["mrg002"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04492488","phase":"1/2","setting":"An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","sponsor":"Shanghai Miracogen Inc.","enrolled":129,"outcomes":[]},"route":"/trials/nct04492488/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/"}]}}